| Depression (Nagel 2018) |
1.72 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Crohns Disease (2017) |
1.33 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Verbal and Numeric Reasoning (VNR) |
2.01 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Breast Cancer |
12.79 |
2 |
1 |
2.2 |
0 |
1 |
IGF2BP2 TCF7L2 |
| Body Mass Index (BMI) (2010) |
5.32 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Fasting Glucose |
8.13 |
2 |
0 |
0.0 |
0 |
1 |
IGF2BP2 TCF7L2 |
| Primary Biliary Cirrhosis |
2.82 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Type 2 Diabetes (T2D) (2012) |
28.78 |
2 |
2 |
4.4 |
0 |
1 |
IGF2BP2 TCF7L2 |
| Blood Platelet Count |
4.65 |
2 |
1 |
2.2 |
0 |
1 |
IGF2BP2 TCF7L2 |
| Blood Red Count |
1.51 |
2 |
0 |
0.0 |
0 |
1 |
IGF2BP2 TCF7L2 |
| Blood White Count |
0.74 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Heel T-Score |
3.38 |
2 |
1 |
2.2 |
0 |
1 |
IGF2BP2 TCF7L2 |
| BMI |
3.85 |
1 |
1 |
2.2 |
0 |
1 |
TCF7L2 |
| Height |
0.27 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Waist Hip Ratio (WHR) |
11.94 |
2 |
2 |
4.4 |
0 |
1 |
IGF2BP2 TCF7L2 |
| Systolic Blood Pressure |
3.06 |
1 |
1 |
2.2 |
0 |
1 |
TCF7L2 |
| Cardiovascular Disease |
2.51 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Hypothyroidism (self reported) |
3.86 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Type 2 Diabetes (T2D) (2018) |
98.23 |
2 |
2 |
4.4 |
0 |
1 |
IGF2BP2 TCF7L2 |
| Lung FEV1/FVC ratio |
3.87 |
2 |
1 |
2.2 |
0 |
1 |
IGF2BP2 TCF7L2 |
| Lung FVC |
2.61 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Chronotype (morning person) |
2.96 |
2 |
0 |
0.0 |
0 |
1 |
IGF2BP2 TCF7L2 |
| Number of treatments/medications taken |
4.05 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Ever used hormone-replacement therapy (HRT) |
2.24 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Ever had hysterectomy (womb removed) |
2.87 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Eye problems/disorders: Diabetes related eye disease |
18.91 |
2 |
0 |
0.0 |
0 |
1 |
IGF2BP2 TCF7L2 |
| Medication: Metformin |
67.16 |
2 |
2 |
4.4 |
0 |
1 |
IGF2BP2 TCF7L2 |
| Diabetes (father) |
67.47 |
2 |
2 |
4.4 |
0 |
1 |
IGF2BP2 TCF7L2 |
| Diabetes (mother) |
49.37 |
2 |
2 |
4.4 |
0 |
1 |
IGF2BP2 TCF7L2 |
| Impedance of leg (right) |
1.48 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Leg fat-free mass (left) |
1.18 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Trunk fat percentage |
1.46 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Hand grip strength (right) |
1.44 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Townsend deprivation index at recruitment |
2.99 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Taking other prescription medications |
2.16 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Bilateral oophorectomy (both ovaries removed) |
2.96 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Heel bone mineral density (BMD) T-score, automated (left) |
2.71 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| High blood pressure |
2.14 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Medication: Levothyroxine sodium |
2.07 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Sitting height |
0.42 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Body mass index (BMI) |
4.01 |
1 |
1 |
2.2 |
0 |
1 |
TCF7L2 |
| Impedance of leg (left) |
1.29 |
2 |
0 |
0.0 |
0 |
1 |
IGF2BP2 TCF7L2 |
| Leg predicted mass (left) |
1.19 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Trunk fat mass |
1.91 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Waist circumference |
2.56 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Alcohol usually taken with meals |
2.44 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Had other major operations |
2.71 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Forced vital capacity (FVC) |
1.51 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Heel bone mineral density (BMD) T-score, automated (right) |
2.43 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Diabetes (self-reported) |
77.30 |
2 |
2 |
4.4 |
0 |
1 |
IGF2BP2 TCF7L2 |
| Medication: Ramipril |
2.89 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Medication: Simvastatin |
8.43 |
2 |
0 |
0.0 |
0 |
1 |
IGF2BP2 TCF7L2 |
| Illnesses of siblings |
5.19 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Weight |
2.31 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Impedance of arm (right) |
2.34 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Arm fat percentage (right) |
2.69 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Trunk fat-free mass |
0.54 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Hip circumference |
7.54 |
1 |
1 |
2.2 |
0 |
1 |
TCF7L2 |
| Worrier / anxious feelings |
5.08 |
2 |
0 |
0.0 |
0 |
1 |
IGF2BP2 TCF7L2 |
| Frequency of tiredness / lethargy in last 2 weeks |
1.88 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Falls in the last year |
2.08 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Forced expiratory volume in 1-second (FEV1) |
3.35 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Medication: Cholesterol lowering |
12.03 |
2 |
0 |
0.0 |
0 |
1 |
IGF2BP2 TCF7L2 |
| Illnesses of mother |
8.93 |
2 |
0 |
0.0 |
0 |
1 |
IGF2BP2 TCF7L2 |
| Forced expiratory volume in 1-second (FEV1), Best measure |
2.74 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Pulse wave Arterial Stiffness index |
2.70 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Impedance of arm (left) |
2.41 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Arm fat mass (right) |
3.12 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Trunk predicted mass |
0.58 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Standing height |
0.31 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Birth weight of first child |
5.02 |
2 |
0 |
0.0 |
0 |
1 |
IGF2BP2 TCF7L2 |
| Peak expiratory flow (PEF) |
5.65 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Medication for cholesterol, blood pressure or diabetes |
7.82 |
2 |
0 |
0.0 |
0 |
1 |
IGF2BP2 TCF7L2 |
| Hypothyroidism/myxoedema (self-reported) |
3.41 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Birth weight |
3.38 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| High blood pressure (siblings) |
3.20 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Forced vital capacity (FVC), Best measure |
0.82 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Body fat percentage |
2.68 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Leg fat percentage (right) |
4.60 |
1 |
1 |
2.2 |
0 |
1 |
TCF7L2 |
| Arm fat-free mass (right) |
1.02 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Comparative body size at age 10 |
0.98 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Wheeze or whistling in the chest in last year |
2.76 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Pulse wave peak to peak time |
2.29 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Medication for pain relief, constipation, heartburn |
3.53 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Medication: Blood pressure |
2.37 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Reproduciblity of spirometry measurement using ERS/ATS criteria |
5.04 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Whole body fat mass |
2.93 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Leg fat mass (right) |
4.28 |
1 |
1 |
2.2 |
0 |
1 |
TCF7L2 |
| Arm predicted mass (right) |
0.93 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Pulse rate, automated reading |
1.73 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Overall health rating |
2.86 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Medication: Aspirin |
9.65 |
2 |
0 |
0.0 |
0 |
1 |
IGF2BP2 TCF7L2 |
| Hypertension (Self-reported) |
2.10 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Illnesses of siblings: Diabetes |
32.09 |
2 |
2 |
4.4 |
0 |
1 |
IGF2BP2 TCF7L2 |
| Forced expiratory volume in 1-second (FEV1), predicted |
1.72 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Whole body fat-free mass |
0.86 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Leg fat-free mass (right) |
1.05 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Arm fat percentage (left) |
2.83 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Long-standing illness, disability or infirmity |
7.88 |
2 |
0 |
0.0 |
0 |
1 |
IGF2BP2 TCF7L2 |
| Diabetes diagnosed by doctor |
87.39 |
2 |
2 |
4.4 |
0 |
1 |
IGF2BP2 TCF7L2 |
| Ever had stillbirth, spontaneous miscarriage or termination |
5.01 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Qualifications: nursing, teaching |
4.56 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Breast cancer (self-reported) |
4.89 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Medication: Aspirin |
11.27 |
2 |
0 |
0.0 |
0 |
1 |
IGF2BP2 TCF7L2 |
| Illnesses of father: None of the above (group 1) |
4.76 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Forced expiratory volume in 1-second (FEV1), predicted percentage |
4.83 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Whole body water mass |
0.86 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Leg predicted mass (right) |
1.08 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Arm fat mass (left) |
2.89 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Number of self-reported non-cancer illnesses |
4.34 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Average weekly champagne plus white wine intake |
3.59 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| High cholesterol (Self-reported) |
3.53 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Medication: Atorvastatin |
12.00 |
2 |
0 |
0.0 |
0 |
1 |
IGF2BP2 TCF7L2 |
| Basal metabolic rate |
1.20 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Leg fat percentage (left) |
4.89 |
1 |
1 |
2.2 |
0 |
1 |
TCF7L2 |
| Arm fat-free mass (left) |
1.21 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Diastolic blood pressure, automated reading |
2.03 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Unable to work because of sickness or disability |
2.22 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Myopia |
2.71 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Vascular/heart problems diagnosed by doctor |
2.79 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Cholesterol lowering medication |
9.69 |
2 |
0 |
0.0 |
0 |
1 |
IGF2BP2 TCF7L2 |
| Heart attack/myocardial infarction (self-reported) |
2.89 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Heart disease (siblings) |
3.71 |
1 |
0 |
0.0 |
0 |
1 |
IGF2BP2 |
| Impedance of whole body |
1.88 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |
| Leg fat mass (left) |
4.43 |
1 |
1 |
2.2 |
0 |
1 |
TCF7L2 |
| Arm predicted mass (left) |
1.16 |
1 |
0 |
0.0 |
0 |
1 |
TCF7L2 |